An autoantibody against Nε-(carboxyethyl)lysine (CEL): Possible involvement in the removal of CEL-modified proteins by macrophages

Biochemical and Biophysical Research Communications

Volumn 407, Issue 2, 2011, Pages 420-425

  Mera, Katsumi ^a   Nagai, Ryoji ^b   Takeo, Kazuhiro ^a   Izumi, Miyoko ^a   Maruyama, Toru ^a   Otagiri, Masaki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPAN WOMEN'S UNIVERSITY   (Japan)

^c SOJO UNIVERSITY   (Japan)

Author keywords

Advanced glycation end products (AGEs); Autoantibody; Macrophages; N (carboxyethyl)lysine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AUTOANTIBODY; LYSINE DERIVATIVE;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RABBIT; SERUM;

ANIMALS; ARGININE; AUTOANTIBODIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MACROPHAGES, PERITONEAL; MICE; RABBITS; SERUM ALBUMIN;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 79953717707     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.040     Document Type: Article

References (37)

1. Hayase F., Nagaraj R.H., Miyata S., Njoroge F.G., Monnier V.M. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J. Biol. Chem. 1989, 264:3758-3764.
2. Sell D.R., Monnier V.M. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J. Biol. Chem. 1989, 264:21597-21602.
3. Ienaga K., Nakamura K., Hochi T., Nakazawa Y., Fukunaga Y., Kakita H., Nakano K. Crosslines, fluorophores in the AGE-related cross-linked proteins. Contrib. Nephrol. 1995, 112:42-51.
4. Ahmed M.U., Thorpe S.R., Baynes J.W. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 1986, 261:4889-4894.
5. Ahmed M.U., Brinkmann Frye E., Degenhardt T.P., Thorpe S.R., Baynes J.W. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J. 1997, 324(Pt 2):565-570.
6. Nagai R., Hayashi C.M., Xia L., Takeya M., Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J. Biol. Chem. 2002, 277:48905-48912.
7. Argirov O.K., Lin B., Ortwerth B.J. 2-ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine) is a newly identified advanced glycation end product in cataractous and aged human lenses. J. Biol. Chem. 2004, 279:6487-6495.
8. Frye E.B., Degenhardt T.P., Thorpe S.R., Baynes J.W. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J. Biol. Chem. 1998, 273:18714-18719.
9. Niwa T., Katsuzaki T., Miyazaki S., Miyazaki T., Ishizaki Y., Hayase F., Tatemichi N., Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J. Clin. Invest. 1997, 99:1272-1280.
10. Nakamura K., Nakazawa Y., Ienaga K. Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. Biochem. Biophys. Res. Commun. 1997, 232:227-230.
11. Makino H., Shikata K., Hironaka K., Kushiro M., Yamasaki Y., Sugimoto H., Ota Z., Araki N., Horiuchi S. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int. 1995, 48:517-526.
12. Suzuki D., Yagame M., Jinde K., Naka R., Yano N., Endoh M., Kaneshige H., Nomoto Y., Sakai H. Immunofluorescence staining of renal biopsy samples in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus using monoclonal antibody to reduced glycated lysine. J. Diabetes Complications 1996, 10:314-319.
13. Murata T., Nagai R., Ishibashi T., Inomuta H., Ikeda K., Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997, 40:764-769.
14. Kume S., Takeya M., Mori T., Araki N., Suzuki H., Horiuchi S., Kodama T., Miyauchi Y., Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. J. Pathol. 1995, 147:654-667.
15. Sakata N., Imanaga Y., Meng J., Tachikawa Y., Takebayashi S., Nagai R., Horiuchi S. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999, 142:67-77.
16. Hammes H.P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA 1991, 88:11555-11558.
17. Degenhardt T.P., Alderson N.L., Arrington D.D., Beattie R.J., Basgen J.M., Steffes M.W., Thorpe S.R., Baynes J.W. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002, 61:939-950.
18. Shibayama R., Araki N., Nagai R., Horiuchi S. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 1999, 48:1842-1849.
19. Vay D., Vidali M., Allochis G., Cusaro C., Rolla R., Mottaran E., Bellomo G., Albano E. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia 2000, 43:1385-1388.
20. Virella G., Thorpe S.R., Alderson N.L., Stephan E.M., Atchley D., Wagner F., Lopes-Virella M.F. Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 2003, 44:487-493.
21. Chen R.F. Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem. 1967, 242:173-181.
22. Ikeda K., Higashi T., Sano H., Jinnouchi Y., Yoshida M., Araki T., Ueda S., Horiuchi S. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996, 35:8075-8083.
23. Mera K., Nagai R., Haraguchi N., Fujiwara Y., Araki T., Sakata N., Otagiri M. Hypochlorous acid generates N(epsilon)-(carboxymethyl)lysine from Amadori products. Free Radic. Res. 2007, 41:713-718.
24. Takata K., Horiuchi S., Araki N., Shiga M., Saitoh M., Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 1988, 263:14819-14825.
25. Lehtimaki T., Lehtinen S., Solakivi T., Nikkila M., Jaakkola O., Jokela H., Yla-Herttuala S., Luoma J.S., Koivula T., Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 1999, 19:23-27.
26. Puurunen M., Manttari M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., Vaarala O., Aho K., Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 1994, 154:2605-2609.
27. Nilsson J., Kovanen P.T. Will autoantibodies help to determine severity and progression of atherosclerosis?. Curr. Opin. Lipidol. 2004, 15:499-503.
28. Yla-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 1994, 14:32-40.
29. Khoo J.C., Miller E., Pio F., Steinberg D., Witztum J.L. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb. 1992, 12:1258-1266.
30. Lopes-Virella M.F., Binzafar N., Rackley S., Takei A., La Via M., Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997, 135:161-170.
31. Arend W.P., Mannik M. Studies on antigen-antibody complexes. II. Quantification of tissue uptake of soluble complexes in normal and complement-depleted rabbits. J. Immunol. 1971, 107:63-75.
32. Bogers W.M., Stad R.K., Janssen D.J., van Rooijen N., van Es L.A., Daha M.R. Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells. Clin. Exp. Immunol. 1991, 86:328-333.
33. Johansson A.G., Lovdal T., Magnusson K.E., Berg T., Skogh T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 1996, 24:169-175.
34. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T., Takashima Y., Kawabe Y., Cynshi O., Wada Y., Honda M., Kurihara H., Aburatani H., Doi T., Matsumoto A., Azuma S., Noda T., Toyoda Y., Itakura H., Yazaki Y., Kodama T., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292-296.
35. Ohgami N., Nagai R., Ikemoto M., Arai H., Kuniyasu A., Horiuchi S., Nakayama H. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J. Biol. Chem. 2001, 276:3195-3202.
36. Ohgami N., Nagai R., Miyazaki A., Ikemoto M., Arai H., Horiuchi S., Nakayama H. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J. Biol. Chem. 2001, 276:13348-13355.
37. Jono T., Miyazaki A., Nagai R., Sawamura T., Kitamura T., Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett. 2002, 511:170-174.